0 Table of Contents |
1 Home |
2 Business Context |
3 Capability Statement |
4 Changelog |
5 Collect Measurements |
6 Complete Care Plan |
7 Consent Based Access Control |
8 Create Care Plan |
9 Create Condition |
10 Create Encounter |
11 Developer Guide |
12 Extensions |
13 Faq |
14 Health Checks |
15 History |
16 In Home Observations |
17 Initial Assesment |
18 Rheumatic Fever Data |
19 Rheumatic Fever Data Models |
20 Rheumatic Fever Examples Cast |
21 Roadmap |
22 Terminology |
23 Artifacts Summary |
23.1 Care In The Community ActivityDefinition Apply Operation |
23.2 Care In The Community PlanDefinition Apply Operation |
23.3 ManaakiNgaTahiAllergyIntolerance |
23.4 ManaakiNgaTahiCarePlan |
23.5 ManaakiNgaTahiCondition |
23.6 ManaakiNgaTahiDocumentReference |
23.7 ManaakiNgaTahiEncounter |
23.8 ManaakiNgaTahiObservation |
23.9 ManaakiNgaTahiPlanDefinition |
23.10 ManaakiNgaTahiServiceRequest |
23.11 ServiceRequestActivityDefinition |
23.12 Template for COVID-19 Care in the Community CCCM MVP Careplans |
23.13 Vital Signs Observation Service Request |
23.14 AIR - Overseas, Historic, Not Done |
23.15 Antiviral medication eligibility questionnaire |
23.16 COVID-19 RAT Result Questionnaire |
23.17 COVID19 Initial Health Assessment Questionnaire |
23.18 COVID19 Public Health History Questionnaire |
23.19 COVID19 Vaccination Side Effects Questionnaire |
23.20 Measles Daily Health Check |
23.21 Mental Health Assessment Survey |
23.22 Post Vaccine Symptom Check day 3 survey |
23.23 Post Vaccine Symptom Check day 42 survey |
23.24 Pregnancy Assessment Survey |
23.25 Question Template for COVID-19 Regular Health Check |
23.26 Report a Rapid Antigen Test (RAT) result |
23.27 ActiveMonitoringDay3SurveyQuestionnaireResponse |
23.28 ActiveMonitoringDay42SurveyQuestionnaireResponse |
23.29 AntiviralEligibilityNoQuestionnaireResponse |
23.30 AntiviralEligibilityYesQuestionnaireResponse |
23.31 ConsumerCOVIDRATResultQuestionnaireResponse |
23.32 COVIDInitialHealthAssessmentQuestionnaireResponse |
23.33 COVIDPublicHealthHistoryQuestionnaireResponseSherrylCarrion |
23.34 COVIDRATResultQuestionnaireResponse |
23.35 COVIDRegularHealthCheckQuestionnaireResponse |
23.36 COVIDVaccinationSurveyQuestionnaireResponse |
23.37 ImmsotVaccinationDataEntryQuestionnaireResponse |
23.38 MeaslesHealthCheckQuestionnaireResponse |
23.39 MentalHealthAssessmentSurveyQuestionnaireResponse |
23.40 PregnancyAssessmentSurveyQuestionnaireResponse |
23.41 CareyCarrington |
23.42 ConditionExample |
23.43 COVID-19 Omicron Response - Carey Carrington |
23.44 DocumentReferenceExample |
23.45 DrDottyMcStuffins |
23.46 EncounterExample |
23.47 ObservationExample |
23.48 ObservationsServiceRequestExample |
23.49 Certainty of rheumatic fever diagnosis |
23.50 Codifies role taken by a whanau member of patient's care team |
23.51 Date of assessment of rheumatic heart disease severity |
23.52 Denotes if the member is to be used a primary contact |
23.53 Frequency of rheumatic fever medication |
23.54 Medications and Follow-up Guidance Questionnaire |
23.55 Patient & whanau goals and preferences questionnaire |
23.56 Reason a rheumatic fever care plan was closed (#revoked status) |
23.57 Reason rheumatic fever care plan changed to on-hold status |
23.58 Relationship of whanau member to patient in care team |
23.59 Rheumatic Fever Care Team |
23.60 Rheumatic Fever CarePlan |
23.61 Rheumatic Fever Condition |
23.62 Rheumatic Fever Medication Request |
23.63 Rheumatic Fever Patient |
23.64 Secondary Prophylaxis Health Assessment Questionnaire |
23.65 Secondary prophylaxis medication allergy questionnaire |
23.66 Severity of rheumatic heart disease |
23.67 Active care plan with medication planned and appointments booked for Madeleine Meringue |
23.68 Basic care plan representing only the registration of Madeleine Meringue |
23.69 Care plan closed with only one appointment completed |
23.70 Care plan underway for Madeleine Meringue with one appointment completed |
23.71 Care plan went on hold after first appointment completed |
23.72 Draft care plan for Madeleine Meringue (no secondary prevention planned) |
23.73 Encounter-SecondaryProphylaxisAppointment |
23.74 LeadProvidersGroup |
23.75 MadeleineMeringue |
23.76 MadeleineMeringueAndWhanau |
23.77 MedicationsAndFollowUpGuidanceQuestionnaireResponse |
23.78 MedicationStatement-August |
23.79 PaniaPunga |
23.80 PatientMedicationAllergyQuestionnaireResponse |
23.81 PatientWhanauGoalsPreferencesQuestionnaireResponse |
23.82 PlannedMedicationRequestExample |
23.83 RFPatientHealthAssessmentQuestionnaireResponse |
23.84 SecondaryProphylaxisAppointment-August-Booked |
23.85 SecondaryProphylaxisAppointment-August-Fulfilled |
23.86 SecondaryProphylaxisAppointment-September-Booked |
23.87 SecondaryProphylaxisAugustEncounterBundle |
23.88 SecondaryProphylaxisCareTeam |
23.89 SecondaryProphylaxisMedicationExample |
23.90 SevereRfConditionExample |
23.91 TeTaiTokerauRFSecondaryPreventionService |
23.92 WaikatoRFSecondaryPreventionService |
23.93 Codes for certainty of diagnosis of rheumatic fever condition |
23.94 Codes for certainty of rheumatic fever diagnosis |
23.95 Codes for differentiating types of external identifiers held in FHIR resource Identifiers |
23.96 Codes for rheumatic fever condition as diagnosed at patient registration |
23.97 External identifier type codes |
23.98 Generic QuestionnaireResponse yes/no question answer codes |
23.99 Rheumatic fever care plan category codes |
23.100 Rheumatic fever care team category codes |
23.101 Rheumatic fever medication allergy codes |
23.102 Rheumatic fever patient care team participant role codes |
23.103 Rheumatic fever planned medication frequency codes |
23.104 Rheumatic heart disease severity codes |
23.105 ManaakiNgaTahiConsent |
23.106 Question Template for COVID-19 Privacy Statement Question |
23.107 ConsentByQuestionnaireExample |
23.108 ConsentByRelatedPersonExample |
23.109 ConsentExample |
23.110 ConsentQuestionnaireResponseExample |
23.111 ProposedConsentBaseExample |
23.112 ProposedConsentCoverageExample |
23.113 RheumaticFeverActiveConsentExample |
23.114 Care In The Community FHIR Server Capability Statement |
23.115 COVID19 vaccines recognised by NZ public health |
23.116 Codings for COVID-19 vaccination brands recognised in New Zealand public health |
23.117 AllergyIntoleranceExample |
23.118 Template for COVID-19 Care in the Community CCCM MVP Careplans |